Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

  • Cejalvo, Juan M.
  • Albanell Mestres, Joan
  • Prat, Aleix
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus primary disease. Metastatic tumors were enriched for proliferation-related and migration-related genes and diminished for luminal-related genes. Expression of proliferation-related genes were better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at predicting OSmet in primary disease compared with metastatic tissue. We observed correlations between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment., This work was supported by funds from Instituto de Salud Carlos III - PI13/01718 (A.P.), by a Career Catalyst Grant from the Susan Komen Foundation (A.P.), by Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (A.P.) and by the Breast Cancer Research Foundation. This work was also supported by funds from FEDER (RETICC): RD12/0036/0076 (JA), RD12/0036/0051 (JA), RD12/0036/0070 (AL) and RD12/0036/0076 (MM). JMC holds a fellowship from “PhD4MD”, a Collaborative Research Training Programme for Medical Doctors (IDIBAPS, August Pi i Sunyer Institute for Biomedical Research and IRB Barcelona, Institute for Research in Biomedicine) partially funded by Instituto de Salud Carlos III, (ISCIII, project: II14/00019). JMC and RRG research support is provided by the Spanish Ministry of Science and Innovation grant SAF2013-46196 (FEDER Funds) and the Generalitat de Catalunya AGAUR 2014-SGR grant 535.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.

  • Slebe Concha, Juan Felipe, 1981-
  • Rojo, Federico
  • Vinaixa, Maria
  • García-Rocha, Mar
  • Testoni, Giorgia
  • Guiu, Marc
  • Planet, Evarist
  • Samino, Sara
  • Arenas, Enrique J.
  • Beltran Marqués, Antoni
  • Rovira Guerín, Ana
  • Lluch, Ana
  • Salvatella, Xavier
  • Yanes, Oscar
  • Albanell Mestres, Joan
  • Guinovart, Joan J. (Joan Josep), 1947-
  • Gomis, Roger R.
The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid production derived from extracellular sources and that the endothelial lipase (LIPG) fulfils this function. LIPG expression allows the import of lipid precursors, thereby contributing to BCa proliferation. LIPG stands out as an essential component of the lipid metabolic adaptations that BCa cells, and not normal tissue, must undergo to support high proliferation rates. LIPG is ubiquitously and highly expressed under the control of FoxA1 or FoxA2 in all BCa subtypes. The downregulation of either LIPG or FoxA in transformed cells results in decreased proliferation and impaired synthesis of intracellular lipids., F.S., E.J.A. and G.T. are supported by the ‘La Caixa’ PhD Fellowship Program. FIS PI12/00680, PI12/01421 and PI12/01552 supported J.A., A.L. and F.R., respectively. J.A. is part of RD12/0036/0051, RD12/0036/0070 and RD12/0036/0042 and F.R. part of biobank PT13/0010/0012. J.A. is the recipient of ISCIII intensification Grant 2014SGR740, XBTC, MARBiobanc and Cellex. R.R.G. was supported by the Institució Catalana de Recerca i Estudis Avançats. Support and structural funds were provided by the BBVA Foundation, the Generalitat de Catalunya (2014 SGR 535) and the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (SAF2013-46196) to R.R.G. and (SAF2014-54525-P) to J.J.G.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.

  • Pavlovic, Milica, 1985-
  • Arnal-Estapé, Anna 
  • Rojo, Federico
  • Bellmunt, Anna 
  • Tarragona, Maria 
  • Guiu, Marc
  • Planet, Evarist
  • Garcia-Albéniz, Xabier
  • Morales, Mònica
  • Urosevic, Jelena 
  • Gawrzak, Sylwia 
  • Rovira Guerín, Ana
  • Prat, Aleix
  • Nonell Mazelon, Lara, 1972-
  • Lluch, Ana
  • Jean-Mairet, Joël 
  • Coleman, Robert 
  • Albanell Mestres, Joan
  • Gomis, Roger R.
BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased screening approach based on selection of highly bone metastatic breast cancer cells in vivo was used to determine copy number aberrations (CNAs) associated with bone metastasis. The CNAs associated with bone metastasis were examined in independent primary breast cancer datasets with annotated clinical follow-up. The MAF gene encoded within the CNA associated with bone metastasis was subjected to gain and loss of function validation in breast cancer cells (MCF7, T47D, ZR-75, and 4T1), its downstream mechanism validated, and tested in clinical samples. A multivariable Cox cause-specific hazard model with competing events (death) was used to test the association between 16q23 or MAF and bone metastasis. All statistical tests were two-sided. RESULTS: 16q23 gain CNA encoding the transcription factor MAF mediates breast cancer bone metastasis through the control of PTHrP. 16q23 gain (hazard ratio (HR) for bone metastasis = 14.5, 95% confidence interval (CI) = 6.4 to 32.9, P < .001) as well as MAF overexpression (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) in primary breast tumors were specifically associated with risk of metastasis to bone but not to other organs. CONCLUSIONS: These results suggest that MAF is a mediator of breast cancer bone metastasis. 16q23 gain or MAF protein overexpression in tumors may help to select patients at risk of bone relapse., MP and SG is supported by “La Caixa” PhD fellowship program. AAE and AB hold PhD fellowships from the Spanish Ministerio de Ciencia e Innovación (MICINN). MTS is supported by the IRB Barcelona PhD program. JU is a “Juan de la Cierva” Researcher (MICINN). FIS PI12/00680, PI12/01552, and PI12/01421 supported JA, ALl, and FR, respectively. JA, ALl, and AP were part of RD12/0036/0051, RD12/0036/0070, and RD12/0036/0042, and FR is part of biobanc RD/09/0076/00101. JA and FR are recipients of intensification grant ISCIII, 2009SGR321, XBTC, MARBiobanc, and Cellex. RRG was supported by the Institució Catalana de Recerca i Estudis Avançats. Support and structural funds were provided by the BBVA Foundation, the Generalitat de Catalunya (2014 SGR 535), and the Spanish Ministerio de Ciencia e Innovación (MICINN) (SAF2013-46196) to RRG.
Repisalud
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

  • Mateo, F
  • Arenas, E J
  • Aguilar, H
  • Serra-Musach, J
  • de Garibay, G Ruiz
  • Boni, J
  • Maicas, M
  • Du, S
  • Iorio, F
  • Herranz-Ors, C
  • Islam, A
  • Prado, X
  • Llorente, A
  • Petit, A
  • Vidal, A
  • Català, I
  • Soler, T
  • Venturas, G
  • Rojo-Sebastian, A
  • Serra, H
  • Cuadras, D
  • Blanco, I
  • Lozano, J
  • Canals, F
  • Sieuwerts, A M
  • de Weerd, V
  • Look, M P
  • Puertas, S
  • García, N
  • Perkins, A S
  • Bonifaci, N
  • Skowron, M
  • Gómez-Baldó, L
  • Hernández, V
  • Martínez-Aranda, A
  • Martínez-Iniesta, M
  • Serrat, X
  • Cerón, J
  • Brunet, J
  • Barretina, M P
  • Gil, M
  • Falo, C
  • Fernández, A
  • Morilla, I
  • Pernas, S
  • Plà, M J
  • Andreu, X
  • Seguí, M A
  • Ballester, R
  • Castellà, E
  • Nellist, M
  • Morales, S
  • Valls, J
  • Velasco, A
  • Matias-Guiu, X
  • Figueras, A
  • Sánchez-Mut, J V
  • Sánchez-Céspedes, M
  • Cordero, A
  • Gómez-Miragaya, J
  • Palomero, L
  • Gómez, A
  • Gajewski, T F
  • Cohen, E E W
  • Jesiotr, M
  • Bodnar, L
  • Quintela-Fandino, M
  • López-Bigas, N
  • Valdés-Mas, R
  • Puente, X S
  • Viñals, F
  • Casanovas, O
  • Graupera, M
  • Hernández-Losa, J
  • Ramón Y Cajal, S
  • García-Alonso, L
  • Saez-Rodriguez, J
  • Esteller, M
  • Sierra, A
  • Martín-Martín, N
  • Matheu, A
  • Carracedo, A
  • González-Suárez, E
  • Nanjundan, M
  • Cortés, J
  • Lázaro, C
  • Odero, M D
  • Martens, J W M
  • Moreno-Bueno, G
  • Barcellos-Hoff, M H
  • Villanueva, A
  • Gomis, R R
  • Pujana, M A
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, F.
  • Arenas, E. J.
  • Aguilar, H.
  • Serra-Musach, J.
  • Ruiz de Garibay, G.
  • Boni, J.
  • Maicas, M.
  • Du, S.
  • Lorio, F.
  • Herranz-Ors, C.
  • Islam, A.
  • Prado, X.
  • Llorente, A.
  • Petit, A.
  • Vidal, A.
  • Catalá, I.
  • Soler, T.
  • Venturas, G.
  • Rojo-Sebastian, A.
  • Serra, H.
  • Cuadras, D.
  • Blanco, I.
  • Lozano, J.
  • Canals, F.
  • Sieuwerts, A. M.
  • Weerd, V. de
  • Look, M. P.
  • Puertas, S.
  • García, N.
  • Perkins, A. S.
  • Bonifaci, N.
  • Skowron, M.
  • Gómez-Baldó, L.
  • Hernández, V.
  • Martínez-Aranda, A.
  • Martínez-Iniesta, M.
  • Serrat, X.
  • Cerón, Julián
  • Brunet, J.
  • Barretina, M. P.
  • Gil, M.
  • Falo, C.
  • Fernández, A.
  • Morilla, I.
  • Pernas, S.
  • Plà, M. J.
  • Andreu, X.
  • Seguí, M. A.
  • Ballester, R.
  • Castellà, E.
  • Nellist. M.
  • Morales, S.
  • Valls, J.
  • Velasco, A.
  • Matias-Guiu, X.
  • Figueras, A.
  • Sánchez-Mut, José Vicente
  • Sánchez-Céspedes, M.
  • Cordero, A.
  • Gómez-Miragaya, J.
  • Palomero, L.
  • Gómez, A.
  • Gajewski, T. F.
  • Cohen, E. E. W.
  • Jesiotr, M.
  • Bodnar, L.
  • Quintela-Fandino, M.
  • López-Bigas, N.
  • Valdés-Mas, R.
  • Puente, X. S.
  • Viñals, F.
  • Casanovas, O.
  • Graupera, M.
  • Hernández-Losa, L.
  • Ramón y Cajal, S.
  • García-Alonso, L.
  • Sáez-Rodríguez, J.
  • Esteller, M.
  • Sierra, A.
  • Martín-Martín, N.
  • Matheu, A.
  • Carracedo, A.
  • González-Suárez, E.
  • Nanjundan, M.
  • Cortés, J.
  • Lázaro, C.
  • Odero, M. D.
  • Martens, J. W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, M. H.
  • Villanueva, A.
  • Gomis, R. R.
  • Pujana, M. A.
13 páginas, 7 figuras, Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure., This study was supported by the following bodies and grants: the Scientific Foundation ‘Asociación Española Contra el Cáncer’ (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodríguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’, MINECO grants SAF2010- 20203 and SAF2013-46196; and the Telemaraton 2014 ‘Todos Somos Raros, Todos Somos Únicos’ grant P35. EJA was supported by ‘la Caixa’ PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.

  • Pavlovic, Milica, 1985-
  • Arnal-Estapé, Anna 
  • Rojo, Federico
  • Bellmunt, Anna 
  • Tarragona, Maria 
  • Guiu, Marc
  • Planet, Evarist
  • Garcia-Albéniz, Xabier
  • Morales, Mònica
  • Urosevic, Jelena 
  • Gawrzak, Sylwia 
  • Rovira Guerín, Ana
  • Prat, Aleix
  • Nonell Mazelon, Lara, 1972-
  • Lluch, Ana
  • Jean-Mairet, Joël 
  • Coleman, Robert 
  • Albanell Mestres, Joan
  • Gomis, Roger R.
BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased screening approach based on selection of highly bone metastatic breast cancer cells in vivo was used to determine copy number aberrations (CNAs) associated with bone metastasis. The CNAs associated with bone metastasis were examined in independent primary breast cancer datasets with annotated clinical follow-up. The MAF gene encoded within the CNA associated with bone metastasis was subjected to gain and loss of function validation in breast cancer cells (MCF7, T47D, ZR-75, and 4T1), its downstream mechanism validated, and tested in clinical samples. A multivariable Cox cause-specific hazard model with competing events (death) was used to test the association between 16q23 or MAF and bone metastasis. All statistical tests were two-sided. RESULTS: 16q23 gain CNA encoding the transcription factor MAF mediates breast cancer bone metastasis through the control of PTHrP. 16q23 gain (hazard ratio (HR) for bone metastasis = 14.5, 95% confidence interval (CI) = 6.4 to 32.9, P < .001) as well as MAF overexpression (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) in primary breast tumors were specifically associated with risk of metastasis to bone but not to other organs. CONCLUSIONS: These results suggest that MAF is a mediator of breast cancer bone metastasis. 16q23 gain or MAF protein overexpression in tumors may help to select patients at risk of bone relapse., MP and SG is supported by “La Caixa” PhD fellowship program. AAE and AB hold PhD fellowships from the Spanish Ministerio de Ciencia e Innovación (MICINN). MTS is supported by the IRB Barcelona PhD program. JU is a “Juan de la Cierva” Researcher (MICINN). FIS PI12/00680, PI12/01552, and PI12/01421 supported JA, ALl, and FR, respectively. JA, ALl, and AP were part of RD12/0036/0051, RD12/0036/0070, and RD12/0036/0042, and FR is part of biobanc RD/09/0076/00101. JA and FR are recipients of intensification grant ISCIII, 2009SGR321, XBTC, MARBiobanc, and Cellex. RRG was supported by the Institució Catalana de Recerca i Estudis Avançats. Support and structural funds were provided by the BBVA Foundation, the Generalitat de Catalunya (2014 SGR 535), and the Spanish Ministerio de Ciencia e Innovación (MICINN) (SAF2013-46196) to RRG.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

  • Cejalvo, Juan M.
  • Albanell Mestres, Joan
  • Prat, Aleix
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus primary disease. Metastatic tumors were enriched for proliferation-related and migration-related genes and diminished for luminal-related genes. Expression of proliferation-related genes were better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at predicting OSmet in primary disease compared with metastatic tissue. We observed correlations between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment., This work was supported by funds from Instituto de Salud Carlos III - PI13/01718 (A.P.), by a Career Catalyst Grant from the Susan Komen Foundation (A.P.), by Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (A.P.) and by the Breast Cancer Research Foundation. This work was also supported by funds from FEDER (RETICC): RD12/0036/0076 (JA), RD12/0036/0051 (JA), RD12/0036/0070 (AL) and RD12/0036/0076 (MM). JMC holds a fellowship from “PhD4MD”, a Collaborative Research Training Programme for Medical Doctors (IDIBAPS, August Pi i Sunyer Institute for Biomedical Research and IRB Barcelona, Institute for Research in Biomedicine) partially funded by Instituto de Salud Carlos III, (ISCIII, project: II14/00019). JMC and RRG research support is provided by the Spanish Ministry of Science and Innovation grant SAF2013-46196 (FEDER Funds) and the Generalitat de Catalunya AGAUR 2014-SGR grant 535.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.

  • Slebe Concha, Juan Felipe, 1981-
  • Rojo, Federico
  • Vinaixa, Maria
  • García-Rocha, Mar
  • Testoni, Giorgia
  • Guiu, Marc
  • Planet, Evarist
  • Samino, Sara
  • Arenas, Enrique J.
  • Beltran Marqués, Antoni
  • Rovira Guerín, Ana
  • Lluch, Ana
  • Salvatella, Xavier
  • Yanes, Oscar
  • Albanell Mestres, Joan
  • Guinovart, Joan J. (Joan Josep), 1947-
  • Gomis, Roger R.
The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid production derived from extracellular sources and that the endothelial lipase (LIPG) fulfils this function. LIPG expression allows the import of lipid precursors, thereby contributing to BCa proliferation. LIPG stands out as an essential component of the lipid metabolic adaptations that BCa cells, and not normal tissue, must undergo to support high proliferation rates. LIPG is ubiquitously and highly expressed under the control of FoxA1 or FoxA2 in all BCa subtypes. The downregulation of either LIPG or FoxA in transformed cells results in decreased proliferation and impaired synthesis of intracellular lipids., F.S., E.J.A. and G.T. are supported by the ‘La Caixa’ PhD Fellowship Program. FIS PI12/00680, PI12/01421 and PI12/01552 supported J.A., A.L. and F.R., respectively. J.A. is part of RD12/0036/0051, RD12/0036/0070 and RD12/0036/0042 and F.R. part of biobank PT13/0010/0012. J.A. is the recipient of ISCIII intensification Grant 2014SGR740, XBTC, MARBiobanc and Cellex. R.R.G. was supported by the Institució Catalana de Recerca i Estudis Avançats. Support and structural funds were provided by the BBVA Foundation, the Generalitat de Catalunya (2014 SGR 535) and the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (SAF2013-46196) to R.R.G. and (SAF2014-54525-P) to J.J.G.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, Francesca|||0000-0002-2342-7010
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Aguilar, Helena
  • Serra-Musach, Jordi
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Boni, Jacopo|||0000-0003-2626-9393
  • Maicas, Miren|||0000-0003-1404-5552
  • Du, Shisuo
  • Iorio, Francesco|||0000-0001-7063-8913
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Islam, Abul
  • Prado, X.
  • Llorente, Alicia
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Vidal, August|||0000-0001-5727-2099
  • Català, Isabel
  • Soler, Teresa
  • Venturas, G.
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Serra, Helena
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Lozano, José
  • Canals, Francesc|||0000-0002-0650-1135
  • Sieuwerts, Anieta M.
  • De Weerd, Vanja
  • Look, Maxime P.
  • Puertas, Sara
  • García, Nadia
  • Perkins, Archibald S.
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Skowron, Margaretha A.
  • Gómez-Baldó, Laia
  • Hernández, Vanessa
  • Martínez-Aranda, Antonio
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Serrat Farran, Xènia|||0000-0001-7611-5400
  • Cerón, Julián|||0000-0003-4739-2243
  • Brunet, Joan|||0000-0003-1945-3512
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil, Mercedes|||0000-0002-7387-2139
  • Falo, Catalina|||0000-0002-5714-6823
  • Fernández, Adela
  • Morilla, Idoia
  • Pernas, Sonia|||0000-0002-1485-5080
  • Plà, Maria Jesus
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester, Rosa|||0000-0002-7870-4185
  • Castellà Fernández, Eva
  • Nellist, Mark D.
  • Morales, Saleta
  • Valls, Joan|||0000-0002-4806-7568
  • Velasco Sánchez, Ana
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Figueras, Agnes
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
  • Cordero Casanovas, Alex|||0000-0002-2224-7122
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • Palomero, Luis|||0000-0002-9144-1017
  • Gomez-Caamaño, Antonio|||0000-0002-9773-4590
  • Gajewski, Thomas F.
  • Cohen, Ezra E. W.
  • Jesiotr, Marzena
  • Bodnar, Lubomir
  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Valdés-Mas, Rafael
  • Puente, Xose S.|||0000-0001-9525-1483
  • Viñals, Francesc|||0000-0002-9918-6751
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Graupera, Mariona|||0000-0003-4608-4185
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Garcia-Alonso, Luz|||0000-0002-7863-9619
  • Saez-Rodriguez, J.
  • Esteller, M.|||0000-0003-4490-6093
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Matheu Fernandez, Ander
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Nanjundan, Meera
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Odero, Maria D.|||0000-0002-8858-2054
  • Martens, John W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, Mary Helen
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.